Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this article, we are going to take a look at where Bristol-Myers Squibb Company ...

The current starter set players can purchase features a few basic components. It includes an adventure booklet, a condensed rulebook for players at 1st-3rd levels, ready-to-play character sheets ...

Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired ...

He has mentioned the firm multiple times in 2025, and most of his comments have focused on Bristol-Myers Squibb Company (NYSE:BMY)’s schizophrenia drug Cobenfy. The stock is up by 18% over the ...

Champions Trophy 2025, PAK vs NZ Highlights: Will Young scored 107(113), while Tom Latham returned unbeaten on 118(104) as New Zealand piled a stiff 320/5 after being invited to bat first.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

The top 10 biopharma M&A deals of 2023 The company is counting heavily on Cobenfy, which was approved in September and was the crown jewel of the $14 billion buyout of Karuna. BMS reported sales ...

The approval of Cobenfy, a new treatment for schizophrenia, has emerged as a potential growth driver for BMY. Analysts view the absence of a Black Box Warning on Cobenfy's label as a positive sign ...